1. Search Result
Search Result
Results for "

μopioid receptors

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

18

Peptides

7

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100122
    Bevenopran
    1 Publications Verification

    CB-5945; ADL-5945

    Opioid Receptor Neurological Disease
    Bevenopran is a peripheral μ-opioid receptor antagonist .
    Bevenopran
  • HY-P1087

    Metorphamide

    Opioid Receptor Cancer
    Adrenorphin is a opioid octapeptide, acting as a potent agonist of μ-opioid receptor, with Ki of 12 nM.
    Adrenorphin
  • HY-128038

    Opioid Receptor Neurological Disease
    N-Desmethyl-loperamide is a major metabolite of loperamide, a drug that selectively activates peripheral μopioid receptors with a Ki value of 0.16 nM. N-Desmethyl-loperamide is a substrate of the ATP-dependent efflux transporter P-glycoprotein .
    N-Desmethyl-loperamide
  • HY-123689

    ALKS-33; RDC-0313

    Opioid Receptor Neurological Disease
    Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .
    Samidorphan
  • HY-13243

    ADL 8-2698; LY 246736

    Opioid Receptor Neurological Disease
    Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan can be used for the research of postoperative ileus .
    Alvimopan
  • HY-76657

    ADL 8-2698 monohydrate; LY 246736 monohydrate

    Opioid Receptor Neurological Disease Cancer
    Alvimopan monohydrate (ADL 8-2698 monohydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan monohydrate has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan monohydrate can be used for the research of postoperative ileus .
    Alvimopan monohydrate
  • HY-P1577

    Opioid Receptor Inflammation/Immunology
    Dermorphin Analog is an analog of Dermorphin. Dermorphin is a natural heptapeptide μ-opioid receptor agonist found in amphibian skin.
    Dermorphin Analog
  • HY-P0244

    Opioid Receptor Neurological Disease
    Dermorphin is a natural heptapeptide μ-opioid receptor (MOR) agonist found in amphibian skin. Inhibition of neuropathic pain .
    Dermorphin
  • HY-76657A

    ADL 8-2698 dihydrate; LY 246736 dihydrate

    Opioid Receptor Neurological Disease Cancer
    Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus .
    Alvimopan dihydrate
  • HY-P0210
    DAMGO
    3 Publications Verification

    DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR .
    DAMGO
  • HY-P0244A

    Opioid Receptor Neurological Disease
    Dermorphin TFA is a natural heptapeptide μ-opioid receptor (MOR) agonist found in amphibian skin. Inhibition of neuropathic pain .
    Dermorphin TFA
  • HY-P3870

    Opioid Receptor Neurological Disease
    DALDA is a potent and highly selective μ-opioid receptor agonist with a Ki of 1.69 nM. DALDA shows antinociceptive and respiratory effects .
    DALDA
  • HY-P3870A

    Opioid Receptor Neurological Disease
    DALDA acetate is a potent and highly selective μ-opioid receptor agonist with a Ki of 1.69 nM. DALDA acetate shows antinociceptive and respiratory effects .
    DALDA acetate
  • HY-P0210B
    DAMGO TFA
    3 Publications Verification

    Opioid Receptor Cancer
    DAMGO TFA is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR .
    DAMGO TFA
  • HY-N0398

    Opioid Receptor Neurological Disease
    Sec-O-Glucosylhamaudol is a natural compound extracted from Peucedanum japonicum Thunb, decreases levels of μ-opioid receptor, with analgesic effect .
    Sec-O-Glucosylhamaudol
  • HY-15122
    Sinomenine
    Maximum Cited Publications
    7 Publications Verification

    NF-κB Opioid Receptor Autophagy Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Sinomenine, an alkaloid extracted from Sinomenium acutum, is a blocker of the NF-κB activation . Sinomenine also is an activator of μ-opioid receptor .
    Sinomenine
  • HY-101011

    Opioid Receptor Infection Neurological Disease
    Naloxonazine dihydrochloride is a specific μ-opioid receptor antagonist with an IC50 of 5.4 nM. Naloxonazine dihydrochloride also shows anti-leishmanial activity .
    Naloxonazine dihydrochloride
  • HY-P3870B

    Opioid Receptor Neurological Disease
    DALDA TFA is a potent and highly selective μ-opioid receptor agonist with a Ki of 1.69 nM. DALDA TFA shows antinociceptive and respiratory effects .
    DALDA TFA
  • HY-15122A
    Sinomenine hydrochloride
    Maximum Cited Publications
    7 Publications Verification

    Cucoline hydrochloride

    NF-κB Opioid Receptor Autophagy Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Sinomenine hydrochloride (Cucoline hydrochloride), an alkaloid extracted from Sinomenium acutum, is a blocker of the NF-κB activation . Sinomenine also is an activator of μ-opioid receptor .
    Sinomenine hydrochloride
  • HY-19902

    GSK1521498 is a potent and selective μ-opioid receptor (MOR) antagonist. GSK1521498 has the potential for disorders of compulsive consumption of food, alcohol, and agents .
    GSK1521498
  • HY-P1502
    β-Endorphin, human
    1 Publications Verification

    Opioid Receptor Neurological Disease
    β-Endorphin, human, a prominent endogenous peptide, existing in the hypophysis cerebri and hypothalamus, is an agonist of opioid receptor, with preferred affinity for μ-opioid receptor and δ-opioid receptor; β-Endorphin, human exhibits antinociception activity.
    β-Endorphin, human
  • HY-A0118

    NKTR-118; AZ-13337019

    Opioid Receptor Neurological Disease
    Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .
    Naloxegol
  • HY-P0186

    Opioid Receptor Neurological Disease
    Endomorphin 2, a high affinity, highly selective agonist of the μ-opioid receptor, displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM.
    Endomorphin 2
  • HY-104006

    Opioid Receptor Neurological Disease
    CYM51010 is a biased ligand of μ-opioid receptor – δ-opioid receptor heterodimers with an EC50 of 403 nM. CYM51010 exhibits anti-nociceptive activity similar to morphine but with a decreased levels of tolerance development and withdrawal symptoms .
    CYM51010
  • HY-115066

    Opioid Receptor Neurological Disease
    GSK1521498 free base is a potent and selective μ-opioid receptor (MOR) antagonist. GSK1521498 free base has the potential for disorders of compulsive consumption of food, alcohol, and agents .
    GSK1521498 free base
  • HY-P0186A

    Opioid Receptor Neurological Disease
    Endomorphin 2 TFA, a high affinity, highly selective agonist of the μ-opioid receptor, displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM .
    Endomorphin 2 TFA
  • HY-A0118A
    Naloxegol oxalate
    2 Publications Verification

    NKTR-118 oxalate; AZ-13337019 oxalate

    Opioid Receptor Neurological Disease
    Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .
    Naloxegol oxalate
  • HY-115066A

    Opioid Receptor Neurological Disease
    GSK1521498 free base (hydrochloride) is a potent and selective μ-opioid receptor (MOR) antagonist. GSK1521498 free base (hydrochloride) is being used for the treatment of disorders of compulsive consumption of food, alcohol, and agents .
    GSK1521498 free base (hydrochloride)
  • HY-153471

    Opioid Receptor Infection Inflammation/Immunology
    MOR agonist-1 is a MOR (μ-opioid receptor) agonist. MOR agonist-1 has good analgesic effect. MOR agonist-1 can be used for the research of pain and pain-related disorders .
    MOR agonist-1
  • HY-P1626

    Opioid Receptor Neurological Disease
    Acetyl tetrapeptide-15 is a synthetic peptide used in the cosmetics for sensitive skin. Acetyl tetrapeptide-15 is derived from endomorphin-2 (Tyr-Pro-Phe-Phe-NH2), a human μ-opioid agonist with selective anti-nociceptive effect. Acetyl tetrapeptide-15 reduces skin hyperreactivity producing inflammatory, chronic and neuropathic pain, by increasing the threshold of neuronal excitability in μ-opioid receptor via an endorphin-like pathway .
    Acetyl tetrapeptide-15
  • HY-P4107

    Opioid Receptor Neurological Disease
    Bilaid C, a tetrapeptide, can be isolated from the Australian estuarine isolate of Penicillium sp. MST-MF667. Bilaid C is also a potent and selective μ-Opioid Receptor (MOPr) agonist (Ki=210 nM, hMOPr) .
    Bilaid C
  • HY-134189

    Opioid Receptor Sigma Receptor Neurological Disease
    EST73502 is a selective, orally active and blood-brain barrier (BBB) penetrant dual μ-opioid receptor (MOR) agonist and σ1 receptor (σ1R) antagonist, with Kis of 64 nM and 118 nM for MOR and σ1R, respectively. EST73502 has antinociceptive activity .
    EST73502
  • HY-P1329

    Opioid Receptor Neurological Disease
    CTOP is a potent and highly selective μ-opioid receptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .
    CTOP
  • HY-P0185
    Endomorphin 1
    1 Publications Verification

    Opioid Receptor Neurological Disease
    Endomorphin 1, a high affinity, highly selective agonist of the μ-opioid receptor (Ki: 1.11 nM), displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. Endomorphin 1 has antinociceptive properties .
    Endomorphin 1
  • HY-P0185A
    Endomorphin 1 acetate
    1 Publications Verification

    Opioid Receptor Neurological Disease
    Endomorphin 1 acetate, a high affinity, highly selective agonist of the μ-opioid receptor (Ki: 1.11 nM), displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. Endomorphin 1 acetate has antinociceptive properties .
    Endomorphin 1 acetate
  • HY-134189A

    Sigma Receptor Opioid Receptor Neurological Disease
    EST73502 monohydrochloride is a selective, orally active and blood-brain barrier (BBB) penetrant dual μ-opioid receptor (MOR) agonist and σ1 receptor (σ1R) antagonist, with Kis of 64 nM and 118 nM for MOR and σ1R, respectively. EST73502 monohydrochloride has antinociceptive activity .
    EST73502 monohydrochloride
  • HY-A0118AS

    Isotope-Labeled Compounds Opioid Receptor Neurological Disease
    Naloxegol-d5 (oxalate) is deuterium labeled Naloxegol (oxalate). Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation[1][2].
    Naloxegol-d5 oxalate
  • HY-P1329A
    CTOP TFA
    1 Publications Verification

    Opioid Receptor Neurological Disease
    CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity .
    CTOP TFA
  • HY-P3517

    β-EP (6-31), human

    Opioid Receptor Neurological Disease Endocrinology
    β-Endorphin, an endogenous opioid neuropeptide, is an opioid receptor agonist. β-Endorphin binds preferentially to μ-opioid receptors and is produced in certain neurons of the central and peripheral nervous system and is one of three endorphins produced in humans. β-Endorphin can be used to reduce stress and maintain homeostasis in the body and is involved in neurological pain perception regulation .
    β-Endorphin (6-31), human
  • HY-N0923

    (+)-Corydaline; Corydalin

    Cholinesterase (ChE) Enterovirus Opioid Receptor Neurological Disease
    Corydaline ((+)-Corydaline), an isoquinoline alkaloid isolated from Corydalis yanhusuo, is an AChE inhibitor with an IC50 of 226 µM. Corydaline is a μ-opioid receptor (Ki of 1.23 µM) agonist and inhibits enterovirus 71 (EV71) replication (IC50 of 25.23 µM). Corydaline has anti-angiogenic, anti-allergic and gastric-emptying and antinociceptive activities .
    Corydaline
  • HY-136208

    Opioid Receptor Neurological Disease
    TAN-452 is an orally active, selective peripherally acting δ-opioid receptor (DOR) antagonist with a Ki of 0.47 nM and a Kb of 0.21 nM. TAN-452 is an antagonist for μ-opioid receptor (MOR; Ki=36.56 nM and Kb=9.43 nM) and κ-opioid receptor (KOR; Ki=5.31 nM and Kb=7.18 nM). TAN-452, a derivative of Naltrindole, demonstrates low brain penetrability and attenuates morphine-induced side effects without affecting pain control .
    TAN-452
  • HY-19627

    S-297995

    Opioid Receptor Neurological Disease Metabolic Disease
    Naldemedine (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine is predicted to bind to 3CL pro encoded by SARS-CoV2 genome .
    Naldemedine
  • HY-19627A

    S-297995 tosylate

    Opioid Receptor Neurological Disease Metabolic Disease
    Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine tosylate is predicted to bind to 3CL pro encoded by SARS-CoV2 genome .
    Naldemedine tosylate
  • HY-155707

    Others Inflammation/Immunology
    MOR agonist-3 (Compound 84) is a D3R/MOR antagonist (Ki 382 nM and 55.2 nM respectively). MOR agonist-3 has the potential to produce analgesic effects through MOR (μ-opioid receptor) (HY-149337) partial agonists and to reduce opioid abuse through D3R antagonists. MOR agonist-3 can be used in the treatment of inflammation and neuropathic pain research .
    MOR agonist-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: